Current understanding of genetic associations with delayed hypersensitivity reactions induced by antibiotics and anti-osteoporotic drugs

Wung, Chih-Hsuan; Wang, Chuang‐Wei; Lai, Kuo-Chu; Chen, Chun‐Bing; Chen, Wei-Ti; Hung, Shuen‐Iu; Chung, Wen‐Hung

doi:10.3389/fphar.2023.1183491

Cited by 2 publications

(1 citation statement)

References 145 publications

(167 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, SMX itself can directly stimulate the immune system by activating T cell receptors via the major histocompatibility complex [ 98 ]. However, regardless of the mechanism implicated in hypersensitivity reactions, these are more common in subjects carrying particular HLA gene variations; among these, reactions involving the HLA-A29, HLA-B12, HLA-DR7, HLA-B44 and HLA A*11:01 gene variations are the most common [ 99 ]. Some authors have suggested that genetic screening should be implemented before the administration of SMX, but no official recommendations in this regard have ever been made [ 100 ].…”

Section: Antibiotics For Which the Role Of Genetics In Conditioning D...mentioning

confidence: 99%

Genetic Variations and Antibiotic-Related Adverse Events

Principi,

Petropulacos,

Esposito

2024

Pharmaceuticals

View full text Add to dashboard Cite

Antibiotic-related adverse events are common in both adults and children, and knowledge of the factors that favor the development of antibiotic-related adverse events is essential to limit their occurrence and severity. Genetics can condition the development of antibiotic-related adverse events, and the screening of patients with supposed or demonstrated specific genetic mutations may reduce drug-related adverse events. This narrative review discusses which genetic variations may influence the risk of antibiotic-related adverse events and which conclusions can be applied to clinical practice. An analysis of the literature showed that defined associations between genetic variations and specific adverse events are very few and that, at the moment, none of them have led to the implementation of a systematic screening process for patients that must be treated with a given antibiotic in order to select those at risk of specific adverse events. On the other hand, in most of the cases, more than one variation is implicated in the determination of adverse events, and this can be a limitation in planning a systematic screening. Moreover, presently, the methods used to establish whether a patient carries a “dangerous” genetic mutation require too much time and waiting for the result of the test can be deleterious for those patients urgently requiring therapy. Further studies are needed to definitively confirm which genetic variations are responsible for an increased risk of a well-defined adverse event.

show abstract

Section: Antibiotics For Which the Role Of Genetics In Conditioning D...mentioning

confidence: 99%